Skip to main content
 

X

 
News

BeiGene News

See all News

  • July 27, 2020
    Priority Review Granted to BeiGene’s New Drug Application of Pamiparib in Ovarian Cancer in China

    Priority Review Granted to BeiGene’s New Drug Application of Pamiparib in Ovarian Cancer in China

  • July 20, 2020
    Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly’s Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection

    Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly’s Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection

  • July 17, 2020
    BeiGene Announces Acceptance of a New Drug Application of Pamiparib in Ovarian Cancer in China

    BeiGene Announces Acceptance of a New Drug Application of Pamiparib in Ovarian Cancer in China

  • July 15, 2020
    BeiGene Announces Closing of Approximately $2.08 Billion Registered Direct Offering

    BeiGene Announces Closing of Approximately $2.08 Billion Registered Direct Offering

  • July 12, 2020
    BeiGene Announces Pricing of Approximately $2.08 Billion Registered Direct Offering

    BeiGene Announces Pricing of Approximately $2.08 Billion Registered Direct Offering

  • July 2, 2020
    BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research

    BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research

  • BeiGene Facts
  • 2010Founded
  • NASDAQ: BGNE  
    HKEX: 06160
    Listings
  • 6Internally Developed
    Clinical Candidates
  • 5Marketed
    Products
    in China
  • 1Approved
    products
    in the U.S.
  • 4100+Global Team
story
 
  • 2010

    • BeiGene was founded as a research and development company
    BeiGene Co-Founders, John V. Oyler and Xiaodong Wang, Ph.D.
  • 2012

    • Began work on an anti-PD-1 antibody and a BTK inhibitor
    Immuno-oncology Therapies
  • 2014

    • Started clinical trials of pamiparib and zanubrutinib
    Clinical Researcher
  • 2016

    • Went public on the Nasdaq, with $182 million initial public offering
    First China biotech to go public on the Nasdaq
  • 2018

    • Established first European office in Switzerland
    • 50+ ongoing or planned clinical trials
    BeiGene expands global operations
  • 2019

    • Received first FDA approval for BRUKINSA™ (zanubrutinib)
    • Received first approval for tislelizumab in China
    2019

Our Story

Breaking Boundaries From the Beginning

From our start in Beijing with a handful of scientists and developers, to today, with a global team, a rich pipeline, strong partnerships, and commercial products. We have accomplished so much in a short time, and yet there is so much still to do.

Our Story

Partnering

Partnerships that Extend Around the Globe

BeiGene is the partner of choice in China for development and commercialization. Read more about our current partnerships and opportunities to build business relationships.

Partners

ZymeworksBioAtla LogoLeapSeattleAmbrx LogoMirati LogoMei PharmaAmgen logoChi-Med LogoAssembly Bio LogoEUSA Logo

Our Patients

Our Commitment to Patients

At BeiGene we are focused not only on the underserved global cancer patient population, but also on individual people fighting their illnesses.

Patients

Careers
 

Careers

Join Our
Team

We’re looking for highly motivated colleagues who can collaborate with us as we build a company that will have a lasting impact on the global fight against cancer.

Careers